Genomic testing for multiple myeloma, colorectal, and bile-duct cancers
Genome Characterization Unit
Comprehensive CLIA-certified genomic testing of tumor, normal tissue, and blood for people with multiple myeloma, colorectal cancer, or cholangiocarcinoma to identify mutations and support care decisions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11191583 on NIH RePORTER |
What this research studies
If you participate, your diagnostic tumor tissue, matched normal tissue, and sometimes blood will be processed under CLIA-compliant procedures for high-quality genetic testing. The program performs deep tumor/normal whole-exome sequencing (~250X), tumor-only whole-genome sequencing (~60X), RNA sequencing, and very deep targeted sequencing (>10,000X) of tumor DNA or cell-free DNA using unique molecular indexes to sensitively detect mutations. Selected samples may also undergo single-cell RNA sequencing, proteomics, and cellular imaging to improve understanding of tumor biology. Testing and planned follow-up collections occur year-by-year within the Washington University PE-CGS program with integrated quality management.
Who could benefit from this research
Good fit: People with a diagnosis of multiple myeloma, colorectal cancer, or cholangiocarcinoma who can provide diagnostic tumor tissue and matched normal samples (and sometimes blood) through the Washington University PE-CGS program.
Not a fit: People without these cancer types, those unable to provide suitable tissue or blood samples, or whose tumors lack clinically actionable mutations may not gain direct benefit.
Why it matters
Potential benefit: Could reveal actionable mutations to help match patients with targeted therapies and enable very sensitive monitoring of tumor mutations over time.
How similar studies have performed: High-depth exome and targeted deep sequencing approaches with UMIs have been successfully used in cancer diagnosis and monitoring, while the integrated use of WES, WGS, RNA-seq and single-cell/proteomic assays is more advanced and partly novel.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Ding, Li — Washington University
- Study coordinator: Ding, Li
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.